Oragenics Inc. (OGEN) was a big mover last session with its shares rising nearly 10% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the recent downtrend of the company as the stock has lost nearly 25% in the past one-month time frame.
This biotechnology company has seen no estimate revision in the last 30 days. The Zacks Consensus Estimate hasn't been in a trend either. Yesterday's price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Oragenics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Investors interested in the biomedical industry may consider stocks like Myriad Genetics Inc. MYGN, Gilead Sciences Inc. GILD and Illumina Inc. ILMN. All three stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
This biotechnology company has seen no estimate revision in the last 30 days. The Zacks Consensus Estimate hasn't been in a trend either. Yesterday's price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Oragenics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Investors interested in the biomedical industry may consider stocks like Myriad Genetics Inc. MYGN, Gilead Sciences Inc. GILD and Illumina Inc. ILMN. All three stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
GILEAD SCIENCES GILD: Free Stock Analysis Report
ILLUMINA INC ILMN: Free Stock Analysis Report
MYRIAD GENETICS MYGN: Free Stock Analysis Report
ORAGENICS INC (OGEN): Get Free Report
To read this article on Zacks.com click here.
Zacks Investment Research
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
